Category - News

Developments

BriaCell technology and clinical data published at the 2019 ASCO

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

May 31, 2019

Markets

Roth starts Atara Biotherapeutics at buy; PT $30

Roth Capital Partners launched coverage of Atara Biotherapeutics (NASDAQ:ATRA) with a “buy” rating and price target of $30. The stock closed at $23.30 on May 29.

May 31, 2019

Markets

Roth starts Marker Therapeutics at buy; PT $10

Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.

May 31, 2019

Markets

Roth starts Forty Seven at buy; PT $28

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

May 29, 2019

Markets

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

May 29, 2019

Markets

Roth starts Corvus Pharma at buy; PT $6

Roth Capital Partners launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and price target of $6. The stock closed at $3.90 on May 28.

May 29, 2019

Developments

Scientus Pharma receives Health Canada approval to sell cannabis oils and capsules

Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis oils and capsules for medical purposes. The company previously obtained its Health Canada license...

May 28, 2019

Developments

IntelGenx receives first shipment of cannabis extract from Tilray for cannabis-infused oral film

IntelGenx (TSXV:IGX; OTCQX:IGXT) recently received the first shipment of cannabis extract from Tilray (NASDAQ:TLRY), providing it with sufficient quantities to commence batch production of cannabis-infused VersaFilm...

May 28, 2019

Markets

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Analyst Marc Goodman of SVB Leerink has assumed coverage of Alder BioPharmaceuticals (NASDAQ:ALDR) with an “outperform” rating and $21 price target. The stock closed at $11.06 on May 24.

May 28, 2019

Markets

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

Novo Holdings A/S has agreed to invest up to £53.5 million in Oxford Biomedica plc (LSE:OXB) in return for new ordinary shares, representing up to 10.1% of the outstanding shares after a capital increase.

May 28, 2019

Category - News

BriaCell technology and clinical data published at the 2019 ASCO

Roth starts Atara Biotherapeutics at buy; PT $30

Roth starts Marker Therapeutics at buy; PT $10

Roth starts Forty Seven at buy; PT $28

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth starts Corvus Pharma at buy; PT $6

Scientus Pharma receives Health Canada approval to sell cannabis oils and capsules

IntelGenx receives first shipment of cannabis extract from Tilray for cannabis-infused oral film

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

General

More